Massive transfusion is defined as replacement of one entire blood volume within 24 hours or more than 50% of blood volume within 3 hours. In a 30 kg dog (blood volume approximately 2,500 mL), this means transfusing over 2.5 liters of blood products in a single day. Having a pre-planned massive transfusion protocol (MTP) reduces mortality by ensuring rapid, organized blood product delivery. Use the Blood Volume Estimates tool to calculate species-specific thresholds and the Blood Transfusion Calculator for component dosing.
The decision to activate an MTP should be made quickly based on clinical assessment rather than waiting for laboratory confirmation. Delays in blood product delivery significantly increase mortality in catastrophic hemorrhage.
Primary activation criteria:
- Estimated blood loss >30-40% of total blood volume (Class III-IV hemorrhagic shock)
- Ongoing hemorrhage unresponsive to 20-30 mL/kg isotonic crystalloid
- PCV dropping rapidly on serial measurement (e.g., drop of >5% per hour)
- Active hemorrhage requiring surgical intervention with ongoing hemodynamic instability
- Need for more than 1.5 mL/kg/min of crystalloid to maintain blood pressure
Common clinical scenarios triggering MTP: Traumatic hemoabdomen, ruptured splenic hemangiosarcoma, severe coagulopathy (rodenticide, DIC), intraoperative hemorrhage, and post-partum hemorrhage.
Having a written, posted MTP in the treatment area streamlines emergency response. The protocol should designate specific roles: who activates the protocol, who retrieves blood products, who prepares the transfusion, who monitors the patient, and who documents the process.
The optimal ratio of packed red blood cells to fresh frozen plasma during massive transfusion has been extensively studied in human trauma medicine, and the consensus strongly favors a 1:1 pRBC:FFP ratio.
The rationale is straightforward: in massive hemorrhage, the patient is losing whole blood, which contains both red cells and plasma with its clotting factors. Replacing only red cells without plasma leads to dilutional coagulopathy, where clotting factor concentrations drop below hemostatic thresholds even if the red cell mass is maintained. This coagulopathy then exacerbates ongoing hemorrhage in a vicious cycle.
Veterinary studies, though limited, support the 1:1 approach. A retrospective study in dogs with hemoabdomen found that patients receiving higher plasma-to-pRBC ratios had improved survival compared to those receiving predominantly pRBC. Some centers advocate for a 1:1:1 ratio (pRBC:FFP:platelet concentrate) when platelets are available.
In practice, if your blood bank has limited products, prioritize maintaining at least a 1:1 pRBC:FFP ratio. If only whole blood is available, this achieves balanced replacement by default.
The "lethal triad" of trauma describes three interrelated physiological derangements that, once established, create a self-reinforcing cycle of deterioration with very high mortality.
Hypothermia: Hemorrhagic shock impairs thermoregulation, and rapid administration of cold blood products (stored at 1-6°C) and crystalloids further drops core temperature. Hypothermia below 35°C impairs coagulation enzyme activity and platelet function, worsening hemorrhage.
Metabolic acidosis: Tissue hypoperfusion from hemorrhage causes lactic acidosis. Stored blood products contain citrate (anticoagulant) that can worsen acidosis. Acidosis impairs coagulation factor function and reduces cardiovascular responsiveness to catecholamines.
Coagulopathy: Consumption of clotting factors in ongoing hemorrhage, dilution from crystalloid resuscitation, and impairment from hypothermia and acidosis combine to produce refractory coagulopathy. This drives further hemorrhage, perpetuating the cycle.
Warning: Breaking the lethal triad requires simultaneous attention to all three components. Warm all fluids and blood products before administration (inline fluid warmers are ideal). Use balanced pRBC:FFP ratios to prevent dilutional coagulopathy. Minimize crystalloid volume. Monitor core temperature continuously and use active warming (forced-air warmers, warm water blankets).
| Parameter | Frequency | Critical Values | Intervention |
|---|---|---|---|
| Ionized Calcium (iCa) | Q30 min | <1.0 mmol/L | Calcium gluconate 50-150 mg/kg IV slowly |
| Potassium | Q30-60 min | >6.0 mEq/L | Insulin/dextrose, calcium gluconate |
| Core Temperature | Continuous | <35°C (95°F) | Active warming, warm all fluids/products |
| PCV / TP | Q30-60 min | PCV <20%, TP <3.5 | Adjust pRBC:FFP delivery rate |
| PT / aPTT | Q60 min | >1.5× normal | Increase FFP ratio, consider cryoprecipitate |
| Lactate | Q60 min | Rising or >5 mmol/L | Reassess perfusion, surgical hemostasis |
| Blood Pressure | Continuous or Q15 min | MAP <60 mmHg | Increase transfusion rate, vasopressors |
| ECG | Continuous | Arrhythmias | Treat underlying electrolyte abnormality |
Citrate is used as the anticoagulant in all stored blood products (CPDA-1, citrate phosphate dextrose adenine). Under normal circumstances, the liver metabolizes citrate rapidly. However, during massive transfusion, the rate of citrate delivery can exceed hepatic metabolism, leading to hypocalcemia as citrate chelates ionized calcium.
Clinical signs of citrate toxicity include hypotension, decreased cardiac contractility, QT prolongation on ECG, muscle tremors, and in severe cases, cardiac arrest. The risk is highest with FFP (which contains more citrate per unit than pRBC) and in patients with hepatic dysfunction.
Monitor ionized calcium every 30 minutes during massive transfusion. When iCa drops below 1.0 mmol/L, administer calcium gluconate 50-150 mg/kg IV slowly over 10-15 minutes while monitoring ECG for bradycardia. Never administer calcium through the same line as blood products, as calcium causes citrated blood to clot.
The massive transfusion protocol should be deactivated when:
- Surgical hemostasis has been achieved
- Hemodynamic stability is maintained without ongoing blood product administration
- PCV and coagulation parameters are trending toward normal
- Lactate is clearing (>20% reduction per hour)
- Urine output is adequate (1-2 mL/kg/hr)
- The clinical team determines the acute hemorrhagic phase has passed
After MTP deactivation, the patient transitions to standard post-transfusion monitoring with serial PCV, coagulation testing, and electrolyte monitoring every 4-6 hours for the first 24 hours. The Hypovolemic Shock Calculator can help guide ongoing fluid support during the recovery phase.
- Activate MTP early when blood loss exceeds 30-40% or hemorrhage is unresponsive to 20-30 mL/kg crystalloid.
- Use a 1:1 pRBC:FFP ratio to prevent dilutional coagulopathy during massive transfusion.
- Monitor ionized calcium every 30 minutes; citrate toxicity causes hypocalcemia and cardiac dysfunction.
- Actively prevent the lethal triad: warm all products, minimize crystalloid, maintain 1:1 component ratios.
- Have a written MTP posted in the treatment area with designated roles for each team member.